OCALA, Fla., July 05, 2023 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. AIM (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, today announced that…Read More
AIM ImmunoTech to Participate in the Virtual Investor Summer Spotlight Series AIM ImmunoTech AMEXAIM
